Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

42.72 +0.49 (+1.16%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	705,704
Open	42.06
Bid (Size)	42.85 (200)
Ask (Size)	43.85 (100)
Prev. Close	42.23
Today's Range	42.06 - 43.40
52wk Range	26.74 - 46.60
Shares Outstanding	63,562,303
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

Today 10:57 EST

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

Today 10:46 EST

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Performance

YTD	-4.0%	-4.0%
1 Month	+2.3%	+2.3%
3 Month	+1.6%	+1.6%
6 Month	+12.0%	+12.0%
1 Year	+11.3%	+11.3%

More News

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

Today 10:38 EST

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

Today 10:29 EST

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

Today 10:21 EST

Via The Motley Fool

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

Via The Motley Fool

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

Via The Motley Fool

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

Via MarketMinute

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

January 12, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026

January 02, 2026

Via MarketMinute

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

Via PredictStreet

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Via The Motley Fool

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

December 05, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 04, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

Via The Motley Fool

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Via The Motley Fool

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

Via The Motley Fool

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

Via The Motley Fool

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

Via The Motley Fool

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Via The Motley Fool

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

December 03, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?

Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.

What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?

Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?

The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market

What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?

The current price of Xenon Pharmaceuticals Inc. - Common Shares is 42.72

When was Xenon Pharmaceuticals Inc. - Common Shares last traded?

The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 02/23/26 04:00 PM ET

What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?

The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 2.72B

How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?

Xenon Pharmaceuticals Inc. - Common Shares has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.